Cargando…

Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance

OBJECTIVE: To ascertain to which extent the use of HbA(1c) and oral glucose tolerance test (OGTT) for diagnosis of glucose tolerance could identify individuals with different pathogenetic mechanisms and cardiovascular risk profile. RESEARCH DESIGN AND METHODS: A total of 844 subjects (44% men; age 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchi, Cristina, Miccoli, Roberto, Bonadonna, Riccardo C., Giorgino, Francesco, Frontoni, Simona, Faloia, Emanuela, Marchesini, Giulio, Dolci, Maria A., Cavalot, Franco, Cavallo, Gisella M., Leonetti, Frida, Del Prato, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507559/
https://www.ncbi.nlm.nih.gov/pubmed/22912427
http://dx.doi.org/10.2337/dc11-2504
_version_ 1782251080766193664
author Bianchi, Cristina
Miccoli, Roberto
Bonadonna, Riccardo C.
Giorgino, Francesco
Frontoni, Simona
Faloia, Emanuela
Marchesini, Giulio
Dolci, Maria A.
Cavalot, Franco
Cavallo, Gisella M.
Leonetti, Frida
Del Prato, Stefano
author_facet Bianchi, Cristina
Miccoli, Roberto
Bonadonna, Riccardo C.
Giorgino, Francesco
Frontoni, Simona
Faloia, Emanuela
Marchesini, Giulio
Dolci, Maria A.
Cavalot, Franco
Cavallo, Gisella M.
Leonetti, Frida
Del Prato, Stefano
author_sort Bianchi, Cristina
collection PubMed
description OBJECTIVE: To ascertain to which extent the use of HbA(1c) and oral glucose tolerance test (OGTT) for diagnosis of glucose tolerance could identify individuals with different pathogenetic mechanisms and cardiovascular risk profile. RESEARCH DESIGN AND METHODS: A total of 844 subjects (44% men; age 49.5 ± 11 years; BMI 29 ± 5 kg/m(2)) participated in this study. Parameters of β-cell function were derived from deconvolution of the plasma C-peptide concentration after a 75-g OGTT and insulin sensitivity assessed by homeostasis model assessment of insulin resistance (IR). Cardiovascular risk profile was based on determination of plasma lipids and measurements of body weight, waist circumference, and blood pressure. Glucose regulation categories by OGTT and HbA(1c) were compared with respect to insulin action, insulin secretion, and cardiovascular risk profile. RESULTS: OGTT results showed 42% of the subjects had prediabetes and 15% had type 2 diabetes mellitus (T2DM), whereas the corresponding figures based on HbA(1c) were 38 and 11%, with a respective concordance rate of 54 and 44%. Subjects meeting both diagnostic criteria for prediabetes presented greater IR and impairment of insulin secretion and had a worse cardiovascular risk profile than those with normal glucose tolerance at both diagnostic methods. In a logistic regression analyses adjusted for age, sex, and BMI, prediabetic subjects, and even more T2DM subjects by OGTT, had greater chance to have IR and impaired insulin secretion. CONCLUSIONS: HbA(1c) identifies a smaller proportion of prediabetic individuals and even a smaller proportion of T2DM individuals than OGTT, with no difference in IR, insulin secretion, and cardiovascular risk profile. Subjects fulfilling both diagnostic methods for prediabetes or T2DM are characterized by a worse metabolic profile.
format Online
Article
Text
id pubmed-3507559
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-35075592013-12-01 Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance Bianchi, Cristina Miccoli, Roberto Bonadonna, Riccardo C. Giorgino, Francesco Frontoni, Simona Faloia, Emanuela Marchesini, Giulio Dolci, Maria A. Cavalot, Franco Cavallo, Gisella M. Leonetti, Frida Del Prato, Stefano Diabetes Care Original Research OBJECTIVE: To ascertain to which extent the use of HbA(1c) and oral glucose tolerance test (OGTT) for diagnosis of glucose tolerance could identify individuals with different pathogenetic mechanisms and cardiovascular risk profile. RESEARCH DESIGN AND METHODS: A total of 844 subjects (44% men; age 49.5 ± 11 years; BMI 29 ± 5 kg/m(2)) participated in this study. Parameters of β-cell function were derived from deconvolution of the plasma C-peptide concentration after a 75-g OGTT and insulin sensitivity assessed by homeostasis model assessment of insulin resistance (IR). Cardiovascular risk profile was based on determination of plasma lipids and measurements of body weight, waist circumference, and blood pressure. Glucose regulation categories by OGTT and HbA(1c) were compared with respect to insulin action, insulin secretion, and cardiovascular risk profile. RESULTS: OGTT results showed 42% of the subjects had prediabetes and 15% had type 2 diabetes mellitus (T2DM), whereas the corresponding figures based on HbA(1c) were 38 and 11%, with a respective concordance rate of 54 and 44%. Subjects meeting both diagnostic criteria for prediabetes presented greater IR and impairment of insulin secretion and had a worse cardiovascular risk profile than those with normal glucose tolerance at both diagnostic methods. In a logistic regression analyses adjusted for age, sex, and BMI, prediabetic subjects, and even more T2DM subjects by OGTT, had greater chance to have IR and impaired insulin secretion. CONCLUSIONS: HbA(1c) identifies a smaller proportion of prediabetic individuals and even a smaller proportion of T2DM individuals than OGTT, with no difference in IR, insulin secretion, and cardiovascular risk profile. Subjects fulfilling both diagnostic methods for prediabetes or T2DM are characterized by a worse metabolic profile. American Diabetes Association 2012-12 2012-11-14 /pmc/articles/PMC3507559/ /pubmed/22912427 http://dx.doi.org/10.2337/dc11-2504 Text en © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Research
Bianchi, Cristina
Miccoli, Roberto
Bonadonna, Riccardo C.
Giorgino, Francesco
Frontoni, Simona
Faloia, Emanuela
Marchesini, Giulio
Dolci, Maria A.
Cavalot, Franco
Cavallo, Gisella M.
Leonetti, Frida
Del Prato, Stefano
Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance
title Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance
title_full Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance
title_fullStr Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance
title_full_unstemmed Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance
title_short Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance
title_sort pathogenetic mechanisms and cardiovascular risk: differences between hba(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507559/
https://www.ncbi.nlm.nih.gov/pubmed/22912427
http://dx.doi.org/10.2337/dc11-2504
work_keys_str_mv AT bianchicristina pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT miccoliroberto pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT bonadonnariccardoc pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT giorginofrancesco pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT frontonisimona pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT faloiaemanuela pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT marchesinigiulio pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT dolcimariaa pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT cavalotfranco pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT cavallogisellam pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT leonettifrida pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT delpratostefano pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance
AT pathogeneticmechanismsandcardiovascularriskdifferencesbetweenhba1candoralglucosetolerancetestforthediagnosisofglucosetolerance